Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab + Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Borderline Resectable Pancreatic Cancer
Conditions
Borderline Resectable Pancreatic Cancer
Trial Timeline
Mar 10, 2024 → Dec 24, 2025
NCT ID
NCT06345300About Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab + Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate
Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab + Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Borderline Resectable Pancreatic Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT06345300. Target conditions include Borderline Resectable Pancreatic Cancer.
What happened to similar drugs?
0 of 4 similar drugs in Borderline Resectable Pancreatic Cancer were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06345300 | Phase 2 | UNKNOWN |
Competing Products
12 competing products in Borderline Resectable Pancreatic Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Olanzapine + placebo | Eli Lilly | Phase 3 | 40 |
| olanzapine | Eli Lilly | Pre-clinical | 26 |
| Olanzapine | Eli Lilly | Phase 3 | 40 |
| Durvalumab + Tremelimumab + Gemcitabine + Cisplatin | AstraZeneca | Phase 2 | 27 |
| quetiapine extended-release + Placebo | AstraZeneca | Phase 3 | 40 |
| Quetiapine fumarate + Placebo | AstraZeneca | Phase 2 | 35 |
| Quetiapine Fumarate | AstraZeneca | Phase 3 | 40 |
| ziprasidone + Placebo | Pfizer | Phase 2 | 35 |
| Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin | Bristol Myers Squibb | Phase 1 | 29 |
| PD-1/PD-L1 inhibitors + Chemotherapy | BeOne Medicines | Phase 2 | 36 |
| Fluorouracil + Irinotecan + Leucovorin + Leucovorin Calcium + Oxaliplatin + Quemliclustat + Zimberelimab | Arcus Biosciences | Phase 1/2 | 33 |
| vafidemstat + Placebo | Oryzon Genomics | Phase 2 | 25 |